Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ionis Pharmaceuticals, Inc. - Common Stock
(NQ:
IONS
)
54.21
-1.44 (-2.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 11, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ionis Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Analyst Expectations for Ionis Pharmaceuticals's Future
↗
June 07, 2023
Via
Benzinga
Ionis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79
↗
May 24, 2023
The Relative Strength Rating for Ionis Pharmaceuticals stock moved into a new percentile Wednesday, as it got a lift from 65 to 79.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
↗
May 04, 2023
Via
Benzinga
Recap: Ionis Pharmaceuticals Q1 Earnings
↗
May 03, 2023
Via
Benzinga
Ionis Pharmaceuticals's Earnings Outlook
↗
May 02, 2023
Via
Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
↗
April 11, 2023
Via
Benzinga
Analyst Ratings for Ionis Pharmaceuticals
↗
March 21, 2023
Via
Benzinga
Ionis Pharmaceuticals's Earnings Outlook
↗
February 21, 2023
Via
Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
↗
January 19, 2023
Via
Benzinga
Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA
↗
April 26, 2023
The FDA approved Biogen Inc's (NASDAQ:
Via
Benzinga
What's Going On With Biogen Stock Tuesday?
↗
April 25, 2023
Biogen Inc (NASDAQ: BIIB) shares are trading lower Tuesday. The company reported first-quarter results before the bell and the FDA approved its ALS therapy Tuesday afternoon.
Via
Benzinga
Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs
↗
April 25, 2023
Via
Benzinga
3 Biotech Stocks to Sell Before They’re 6 Feet Under
↗
April 24, 2023
Biotech stocks with no earnings, no cash, and no path to profit will have no chance at survival. Here's three such biotech stocks to avoid.
Via
InvestorPlace
AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression
↗
April 24, 2023
Via
Benzinga
Could This Rare-Disease Drug Candidate Become a Blockbuster?
↗
April 19, 2023
This drug candidate could be a great treatment option for patients with a potentially deadly disease.
Via
The Motley Fool
The Latest Analyst Ratings for Ionis Pharmaceuticals
↗
December 21, 2022
Via
Benzinga
Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed
↗
December 13, 2022
Via
Benzinga
4 Analysts Have This to Say About Ionis Pharmaceuticals
↗
November 10, 2022
Analysts have provided the following ratings for Ionis Pharmaceuticals (NASDAQ:IONS) within the last quarter:
Via
Benzinga
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward'
↗
April 12, 2023
SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy...
Via
Benzinga
AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review
↗
March 27, 2023
Via
Benzinga
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
↗
March 23, 2023
The companies are focusing on a small population of ALS patients with a genetic mutation.
Via
Investor's Business Daily
FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder
↗
March 23, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
↗
March 21, 2023
Via
Benzinga
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year
↗
March 16, 2023
Via
Benzinga
Analyst Says Ionis' Additional Hereditary Angioedema Study Data Supports 'Highly Competitive Profile'
↗
February 21, 2023
Via
Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
↗
February 02, 2023
The company that remains still has a large pipeline of non-migraine assets.
Via
Investor's Business Daily
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
January 09, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
January 04, 2023
From
Biogen Inc.
Via
GlobeNewswire
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
↗
November 16, 2022
Neurodegenerative disorders could mean big bucks for some biotechs.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022
↗
December 21, 2022
Via
Benzinga
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
